JYB-1907

N/A

Report date: 2023/06/16 13:59:16

Base Information

Drug NameJYB-1907
Drug Alias NameJYB-1907
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTransforming growth factor beta activator LRRC32 inhibitorsTransforming growth factor beta 1 inhibitors
TargetsTransforming growth factor beta activator LRRC32Transforming growth factor beta 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangxi Jemincare Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Jiye Biopharmaceutical Co LtdShanghai Jiyu Pharmaceutical Technology Co LtdJiangxi Jemincare Group Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A